

In 2007, intravitreal bevacizumab was used with promise in neonates with aggressive posterior retinopathy of prematurity (ROP). A landmark study by Mintz-Hittner et al. (BEAT-ROP study) established anti-VEGF injections as the first-line therapy for stage 3 zone 1 ROP .